HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Venus Remedies secures renewal of DSIR R&D recognition for VMRC
Jun-04-2026

Venus Remedies has secured the renewal of in-house Research & Development (R&D) recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D unit, Venus Medicine Research Centre (VMRC).

DSIR recognition is granted to organisations that operate a dedicated in-house R&D unit with defined research objectives, qualified scientific staff, and separately accounted R&D expenditure. The renewal confirms that VMRC continues to meet these conditions.

The recognition supports VMRC's ongoing work in antimicrobial resistance, including the development of VRP-034, a novel polymyxin 8 formulation that holds USFDA Qualified Infectious Disease Product (QIDP) designation, and the GASAR resistance surveillance study.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

  RELATED NEWS >>